rnase l

RNase L-IN-1 (compound 17a) functions as an inhibitor of RNase L (Ribonuclease L), an enzyme responsible for RNA degradation to inhibit viral replication and mediate innate immune responses and inflammation [1].

RNAse L RIBOTAC (compound C64) is an RNA-degrading chimera that binds to a four-way RNA helix called SL5 located in the 5’ UTR of the SARS-CoV-2 RNA genome, thereby inhibiting viral replication in pulmonary epithelial cancer cells.

RNase L ligand 1 (Compound F1-COOH) serves as a ligand for RNase L and is utilized in the synthesis of F1-RIBOTAC.

RNase L ligand 3 is an RNase L ligand employed in the synthesis of F3-PEG8-RiboTAC.

RNase L-IN-2 is an activator of RNase L with EC50 of 22 uM; shows broad-spectrum antiviral activity against diverse types of RNA viruses, including the human pathogen human parainfluenza virus type 3, with no cytotoxic at the effective concentrations.

RNA recruiter 1 is the RNA ligand segment of RNAse L RIBOTAC, an RNA degradation chimera capable of binding the four-stranded RNA helix SL5 in the 5' untranslated region of the SARS-CoV-2 RNA genome, thereby inhibiting viral replication in lung epithelial carcinoma cells. RNA recruiter 1 is useful for the synthesis of RIBOTAC.

F1-RIBOTAC is a ribonuclease-targeting chimera (RIBOTAC) that reduces QSOX1-amRNA expression through an RNase L-dependent mechanism. It is applicable in cancer research. (Pink: RNA ligand; Black: linker; Blue: RNase L ligand.)

RNA recruiter-linker 1 is part of the RNA ligand-linker in RNAse L RIBOTAC, which is an RNA-degrading chimera designed to bind the four-stranded RNA helix SL5 within the 5' untranslated region of the SARS-CoV-2 RNA genome. This binding inhibits the replication of the virus in lung epithelial carcinoma cells. RNA recruiter-linker 1 is also useful in RIBOTAC synthesis.

2-5A (5'-O-Triphosphoryladenylyl-(2'→5')-adenylyl-(2'→5')-adenosine) pentasodium is a 5'-triphosphorylated (2',5') oligo-adenylate. Acting as an immune mediator, 2-5A pentasodium enhances the activity of RNase L. It degrades viral mRNA and inhibits protein synthesis by binding to RNase L and activating its ribonuclease function. This compound is useful in research related to respiratory syncytial virus (RSV) and cancer.

F3-PEG8-RiboTAC is a RiboTAC compound that specifically degrades the mRNA of the oncogene LGALS1. This compound can induce apoptosis (cell death) in tumor cells and inhibit their invasion. F3-PEG8-RiboTAC exhibits antitumor activity and is applicable in research on leukemia and triple-negative breast cancer. (RNase L ligand; RNA binder; Linker)

2-5A is a 5'-triphosphorylated (2',5') oligoadenylate. It acts as an immune messenger capable of enhancing RNase L immunity. By binding to RNase L and activating its endoribonuclease activity, 2-5A degrades viral mRNA and inhibits protein synthesis. This compound is useful in research on respiratory syncytial virus (RSV) and cancer.

L-696229 is a specific inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT). L-696229 inhibited RT activity in a mutually exclusive manner with respect to either phosphonoformate or azidothymidine triphosphate and was a weak

The compound 2'-RIBOTAC-U recruiter-linker (Compound 9) is composed of an RNase L recruiter and a linker. It reacts via copper-catalyzed click chemistry with either 2’-azido-uridine or 5’-azidomethyl-uridine to form 2'-RIBOTAC-U and 5'-RIBOTAC-U, respectively. Notably, 2'-RIBOTAC-U exhibits activity against SARS-CoV-2.